Novo Nordisk (NYSE:NVO) provides an update on its share repurchase programme conducted under EU Safe Harbour rules. The 12‑month programme, running from 4 February 2026, targets up to DKK 15 billion in B share buybacks, including up to DKK 11,200,000,010.45 under the tranche initiated 6 May 2026.
From 27 July to 3 August 2026, Novo Nordisk repurchased B shares bringing the accumulated amount under this tranche to 12,305,000 shares for DKK 3,733,256,468. Since 4 February 2026, it has bought back 27,064,179 B shares at an average price of DKK 278.35, totalling DKK 7,533,256,457. Novo Nordisk now holds 44,249,480 B shares as treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.
Loading…
Loading translation…
Positive
Share repurchase target up to DKK 15 billion over 12 months beginning 4 February 2026
DKK 11.2 billion maximum allocation for B share buybacks in tranche starting 6 May 2026
27,064,179 B shares repurchased since 4 February 2026 for DKK 7,533,256,457
Average repurchase price of DKK 278.35 per B share since 4 February 2026
Treasury holding at 44,249,480 B shares, representing 1.0% of share capital
+0.70%
Vs previous close
$44.59
Last Price
$43.68
$49.15
Day Range
$197.17B
Market Cap
4.3x
Rel. Volume
Following this news, NVO has gained 0.70%, reflecting a mild positive market reaction.
Our momentum scanner has triggered 30 alerts so far, indicating elevated trading interest and price volatility.
The stock is currently trading at $44.59.
Trading volume is very high at 4.3x the average, suggesting strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
See more from StockTitan in Google Search and AI answers.
Adds StockTitan as a preferred source · opens Google
08/04/2026 – 09:40 AM
Bagsværd, Denmark, 4 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 27 July 2026, the following transactions have been made:
Number of
B sharesAverage
purchase priceTransaction
value, DKKAccumulated, last announcement11,160,000 3,362,368,90327 July 2026195,000324.5563,286,94428 July 2026190,000330.1662,729,80029 July 2026185,000335.9862,155,88330 July 2026185,000333.1561,632,34531 July 2026200,000315.0863,016,3763 August 2026190,000305.6158,066,217Accumulated under the programme12,305,000 3,733,256,468
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 44,249,480 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 3 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 27,064,179 B shares at an average share price of DKK 278.35 per B share equal to a transaction value of DKK 7,533,256,457.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Company announcement No 46 / 2026
20260804_safe harbour transaction details
FAQ
What is included in the Novo Nordisk (NVO) share repurchase programme announced for 2026?
The programme covers repurchases of B shares for up to DKK 15 billion over 12 months from 4 February 2026. According to Novo Nordisk, this includes a specific tranche of up to DKK 11,200,000,010.45 running from 6 May 2026 to 1 February 2027.
How many Novo Nordisk (NVO) shares have been repurchased as of 3 August 2026?
As of 3 August 2026, Novo Nordisk has repurchased 27,064,179 B shares since 4 February 2026. According to Novo Nordisk, these shares were bought at an average price of DKK 278.35, for a total transaction value of DKK 7,533,256,457.
What portion of Novo Nordisk (NVO) share capital is held as treasury shares after the 2026 buybacks?
Following recent transactions, Novo Nordisk holds 44,249,480 B shares as treasury shares. According to Novo Nordisk, this corresponds to 1.0% of the company’s total share capital of 4,465,000,000 A and B shares, including treasury shares.
What were the latest weekly share repurchases by Novo Nordisk (NVO) in July–August 2026?
Between 27 July and 3 August 2026, Novo Nordisk executed several daily B share repurchases. According to Novo Nordisk, these brought accumulated purchases under the current tranche to 12,305,000 B shares with a total transaction value of DKK 3,733,256,468.
Under which regulations is Novo Nordisk’s 2026 share buyback (NVO) being conducted?
The 2026 share repurchase is conducted under Article 5 of Regulation No 596/2014 (MAR) and the EU Safe Harbour rules. According to Novo Nordisk, the programme follows Commission Delegated Regulation (EU) 2016/1052, providing a regulatory framework for market buyback operations.
Where can investors find detailed daily transaction data for the Novo Nordisk (NVO) 2026 buyback?
Daily transaction details are published on novonordisk.com. According to Novo Nordisk, each transaction made under the 2026 share repurchase programme is disclosed there, allowing investors to track repurchased volumes, average purchase prices and transaction values over time.